Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
271 articles about Coherus BioSciences
-
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
5/11/2022
Coherus Biosciences, Inc. announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors.
-
Coherus BioSciences Management to Present at Upcoming Investor Conferences
5/10/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ET UBS Global Healthcare Conference on Tuesday, May 24 at 2:00 p.m. ET.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Coherus BioSciences Reports First Quarter 2022 Results
5/5/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2022 and recent business highlights.
-
Coherus BioSciences Appoints Charlie Newton to Board of Directors
5/5/2022
Coherus BioSciences, Inc. today announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors.
-
Coherus BioSciences Announces New Employment Inducement Grants - May 04, 2022
5/4/2022
Coherus BioSciences, Inc., announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the common stock of the Company to 13 newly hired employees with a per share exercise price of $9.28, the closing trading price on the grant date.
-
The FDA is quickly catching up after COVID-19 disrupted typical review timelines and planned inspections and Monday morning held bad news for Coherus, Junshi and Axsome.
-
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
5/2/2022
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”).
-
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
5/2/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, “Junshi”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for toripalimab in combination with gemcitabine and cisplatin.
-
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
4/29/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022.
-
Bristol Myers Squibb will hear from the FDA on April 28 about Mavacamten, while Supernus, Axsome, Coherus, Hutchmed and Incyte also await the fate of their respective drug candidates.
-
Junshi Biosciences and Coherus Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
4/14/2022
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).
-
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
4/14/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).
-
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
4/9/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study, a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
4/8/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study, a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
-
Coherus BioSciences Announces New Employment Inducement Grants - Apr 05, 2022
4/5/2022
Coherus BioSciences, Inc., announced that effective March 31, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.91, the closing trading price on the grant date.
-
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
3/29/2022
Coherus BioSciences, Inc., beginning at 9:30 a.m. Eastern Daylight Time , is hosting a meeting with analysts and investors to present the Company’s corporate strategy to build a leading innovative immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.
-
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
3/22/2022
Coherus BioSciences, Inc. today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
3/15/2022
Shanghai Junshi Biosciences Co., and Coherus Biosciences today announced the presentation of positive results and biomarker analyses from the pivotal study “CHOICE-01” (clinicaltrials.gov identifier# NCT03856411).